Abstract
In the present study, 3D-QSAR analysis was performed on a set of 37 TGF-β inhibitors utilizing pharmacophore based alignment to uncover the essential structural and steric features of these newly discovered b-annulated 1,4- dihydropyridine (1,4-DHP) molecules to get better antagonism of the TGF-β receptor. The best 3D-QSAR model identified with PLS factor 4 that had the highest values of external predictability parameters exhibited Q2 (0.8972), and R2 (0.9826) and displayed high values of F (281.9) and low SD (0.0785). This selected model was validated statistically by determining Pearson-r (0.9718) for test set molecules. Contours thus obtained from different properties generated using our QSAR model explained the variation in the activity of dataset with respect to different attachments in the core structure. This would help to make suitable structural modifications in 1, 4-DHP molecules so as to make a better complementary fit to the active site of TGF-β receptor, which in turn would improve the potency of newly designed molecules.
Keywords: Atom based QSAR, Pharmacophore, TGFβ signalling, Cardiogenesis.
Letters in Drug Design & Discovery
Title:Pharmacophore and 3D QSAR Study of TGFβ Inhibitors
Volume: 11 Issue: 3
Author(s): Mohamed Asraf Vazhapully, D. Vinod and N.H. Zeinul Hukuman
Affiliation:
Keywords: Atom based QSAR, Pharmacophore, TGFβ signalling, Cardiogenesis.
Abstract: In the present study, 3D-QSAR analysis was performed on a set of 37 TGF-β inhibitors utilizing pharmacophore based alignment to uncover the essential structural and steric features of these newly discovered b-annulated 1,4- dihydropyridine (1,4-DHP) molecules to get better antagonism of the TGF-β receptor. The best 3D-QSAR model identified with PLS factor 4 that had the highest values of external predictability parameters exhibited Q2 (0.8972), and R2 (0.9826) and displayed high values of F (281.9) and low SD (0.0785). This selected model was validated statistically by determining Pearson-r (0.9718) for test set molecules. Contours thus obtained from different properties generated using our QSAR model explained the variation in the activity of dataset with respect to different attachments in the core structure. This would help to make suitable structural modifications in 1, 4-DHP molecules so as to make a better complementary fit to the active site of TGF-β receptor, which in turn would improve the potency of newly designed molecules.
Export Options
About this article
Cite this article as:
Vazhapully Asraf Mohamed, Vinod D. and Hukuman Zeinul N.H., Pharmacophore and 3D QSAR Study of TGFβ Inhibitors, Letters in Drug Design & Discovery 2014; 11 (3) . https://dx.doi.org/10.2174/157018081131000071
DOI https://dx.doi.org/10.2174/157018081131000071 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Current Status of Renal Arterial Endovascular Interventions
Current Hypertension Reviews Safety and Efficacy of Intracoronary Human Umbilical Cord-Derived Mesenchymal Stem Cell Treatment for Very Old Patients with Coronary Chronic Total Occlusion
Current Pharmaceutical Design CD36 as a Therapeutic Target for Endothelial Dysfunction in Stroke
Current Pharmaceutical Design Experimental Models of Abdominal Aortic Aneurysms: An Overview
Current Pharmaceutical Design Functions of S100 Proteins
Current Molecular Medicine Three-dimensional Printing-Driving Liver Therapies
Current Medicinal Chemistry Phyto-derived Products as Matrix Metalloproteinases Inhibitors in Cardiovascular Diseases
Current Hypertension Reviews The Coronary Collateral Circulation in Man
Current Cardiology Reviews Myocardial Infarction after Rituximab Treatment for Rheumatoid Arthritis: Is there a Link?
Current Pharmaceutical Design Intracranial Aneurysms; In Need of Early Diagnostic and Treatment Using Bio- and Nanotechnology
Current Medicinal Chemistry The Appearance of Middle Meningeal Artery Fistulae After Willis Covered Stent for Traumatic Carotid-cavernous Fistulae: Two Case Reports
Current Medical Imaging Molecular Mechanisms and Therapeutic Application of NSAIDs and Derived Compounds in Alzheimers Disease
Current Alzheimer Research The Renin-Angiotensin System and the Cerebrovascular Diseases: Experimental and Clinical Evidence
Protein & Peptide Letters Protein-Energy Malnutrition Alters Thermoregulatory Homeostasis and the Response to Brain Ischemia
Current Neurovascular Research Autophagy after Subarachnoid Hemorrhage: Can Cell Death be Good?
Current Neuropharmacology Platelet Activating Factor/Platelet Activating Factor Receptor Pathway as a Potential Therapeutic Target in Autoimmune Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Complications of Infective Endocarditis
Cardiovascular & Hematological Disorders-Drug Targets The Challenges of Blood Pressure Control in Dialysis Patients
Recent Advances in Cardiovascular Drug Discovery (Discontinued) Mass Spectrometric Analysis of F2-Isoprostanes: Markers and Mediators in Human Disease
Current Pharmaceutical Analysis Calreticulin in the Heart: From Embryological Development to Cardiac Pathology.
Current Molecular Medicine